Rapid progression of Barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient  by Saleh, Waleed et al.
BRIEF CLINICAL REPORTSRapid progression of Barrett’s esophagus into adenocarcinoma in
a combined lung and kidney transplant recipientWaleed Saleh, MD, Andre Duranceau, MD, Jocelyne Martin, MD, Nicolas Noiseux, MD,
Charles Poirier, MD, and Pasquale Ferraro, MD, Montreal, Quebec, CanadaThe incidence of cancer in solid organ transplant recipients
is significantly greater than that of the general population.
This increase is related to the intensity and duration of the
immunosuppressive therapy. We herein present a rare case
in which Barrett’s esophagus (BE) rapidly progressed into
invasive adenocarcinoma after a patient with scleroderma
underwent combined lung and kidney transplantation.CLINICAL SUMMARY
A 56-year-old male patient with scleroderma and pulmo-
nary fibrosis (IPF) was referred to our lung transplant pro-
gram. The patient presented with progressive dyspnea over
a 2-year period. While on treatment, his condition deterio-
rated progressively until he became oxygen dependent.
The pretransplant workup revealed a forced expiratory vol-
ume in 1 second of 53%, forced vital capacity of 47%, and
diffusing capacity for carbon monoxide of 13%. Computed
tomography (CT) scan showed pulmonary infiltrates consis-
tent with IPF. An upper gastrointestinal endoscopy showed
the presence of BE at 29 cm. Biopsies confirmed BE with
metaplasia but no evidence of dysplasia. The renal function
was moderately impaired with a serum creatinine of 141 and
a creatinine clearance of 36 mL/min. The patient had a thor-
ough evaluation by the transplant nephrologists, who con-
firmed the renal insufficiency. The patient was thus listed for
a combined double lung and kidney transplantation. While
on the waiting list, the chest CT scan was repeated 3 times
at 6-month intervals and remained unremarkable.
After a 21-month wait, the recipient underwent a sequen-
tial double-lung transplant on cardiopulmonary bypass.
Once stabilized hemodynamically, a heterotopic kidney
transplant was performed.
Postoperatively, immunosuppression consisted of basilix-
imab for induction and methylprednisolone/prednisone, ta-
crolimus, and mycophenolate mofetil as maintenance
therapy. After being extubated on postoperative day 4, the
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On postoperative day 14, a tracheostomy was carried out
and the patient was then successfully weaned from the ven-
tilator. Seven weeks postoperatively, blood was found in the
nasogastric tube. Endoscopy revealed a large mass at the dis-
tal esophagus, which on biopsy was confirmed to be a poorly
differentiated adenocarcinoma. CT scan showed an 8-cm
mass of the distal esophagus (Figure 1). Due to the patient’s
overall condition and the apparent aggressiveness of the
esophageal cancer, only comfort measures were instituted.
The patient died 8 weeks after his transplantation.DISCUSSION
The incidence of cancer in transplant recipients is in-
creased secondary to the immunosuppressive therapy. This
is especially noteworthy in patients with premalignant con-
ditions. Reports have shown that in renal transplant recipi-
ents, the incidence of skin tumors is increased 30-fold,1
and posttransplant lymphoproliferative disorder predomi-
nates in lung transplant recipients, most likely as a result
of the more intense immunosuppression.2
BE is a well-documented premalignant lesion. Endo-
scopic surveillance is generally recommended every 18 to
24 months, with follow-up at shorter intervals if there is
a concern for dysplasia on histology. Once high-grade dys-
plasia develops, patients should be considered for esopha-
gectomy, unless they are poor surgical candidates.
Immunosuppression may play an important role in the
malignant transformation of BE into adenocarcinoma asFIGURE 1. Computed tomography scan at the level of the lower chest
showing large mass arising from the distal esophagus.
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Brief Clinical Reportssuggested by Oka and colleagues.3 The authors found that
patients with BE have significant suppression of T-cell and
B-cell function as well as interlukin-2 production. In addi-
tion, Hsu and associates4 reported a case of metastatic
esophageal cancer arising in BE in a patient with chronic
lymphocytic leukemia with documented B-cell dysfunction.
In the present report, the use of induction therapy followed
by intense immunosuppression certainly placed the BE at
increased risk for malignant transformation.
It is possible that the metaplasia in this patient may have
progressed into high-grade dysplasia prior to the transplan-
tation, taking into consideration the 22-month gap between
the diagnosis of metaplasia and the transplant. Endoscopic
surveillance during the waiting period would have permitted
an early diagnosis; however, this was not possible in view of
the patient’s poor pulmonary status.
Only one case of rapid progression of BE to adenocarci-
noma has been reported after liver transplantation,5 and to
our knowledge, the present case is the first reported after
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218 The Journal of Thoracic and Cardiovascular SurgIt becomes essential to ask whether the diagnosis of BE in
pretransplant patients precludes them frombeing transplanted.
Although there is no clear answer, there is no doubt that these
patients should undergo upper gastrointestinal endoscopy on
a regular basis prior to their transplant. Close surveillance
after transplantation is certainly warranted to detect signs of
dysplasia. Should high-grade dysplasia occur, adjustment
of the immunosuppressive therapy is necessary and ablation
or resection of the dysplastic mucosa should be considered.
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with left ventricular apical aneurysmLokeswara Rao Sajja, MS, MCh, MD, FACS, and Gopichand Mannam, FRCS (Glasg), FRCS(Ed), FRCS
(CT), Hyderabad, IndiaAccessory mitral valve tissue is a rare congenital cardiac
anomaly, an uncommon cause of left ventricular outflow
tract (LVOT) obstruction, and usually diagnosed during
childhood. We report a case of a nonobstructive accessory
mitral valve in a 33-year-old woman who was evaluated
for systemic embolization that resulted in right hemiplegia.
A mass lesion was diagnosed in the apical region of the
left ventricular (LV) cavity by means of transthoracic and
transesophageal echocardiography. A cardiac magnetic res-
onance image (MRI) showed a mass lesion in the LV cavity
and LV apical aneurysm. The patient had undergone suc-cessful excision of the mass lesion, which was accessory mi-
tral valve tissue, and linear repair of the LV aneurysm.CLINICAL SUMMARY
A 33-year-old woman who recovered from right hemiple-
gia was referred to our center with a diagnosis of an intraca-
vitory mass lesion of the left ventricle. On physical
examination, she had a regular pulse, with a rate of 80
beats/min and a blood pressure of 126/80 mm Hg. Her first
and second heart sounds were normal, and there was no mur-
mur. An electrocardiogram showed sinus rhythm. She was
evaluated with transthoracic and transesophageal 2-dimen-
sional echocardiography and Doppler scanning, which
showed a mass in the LV cavity, and there was no gradient
across the LVOT. A cardiac MRI demonstrated a mass le-
sion in the LV cavity attached to the distal interventricular
septum and LV apical aneurysm (Figure 1, A). A coronary
angiogram showed normal epicardial coronary arteries.
She underwent excision of accessory mitral valve tissue
and linear repair of the LV aneurysm through a standard
median sternotomy during cardiopulmonary bypass. Theery c January 2010
